{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:07:18Z","timestamp":1790298438605,"version":"4.1.0"},"reference-count":29,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1136\/jnnp-2015-312940","type":"journal-article","created":{"date-parts":[[2016,2,25]],"date-time":"2016-02-25T23:09:17Z","timestamp":1456441757000},"page":"885-889","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":142,"title":["Extended interval dosing of natalizumab in multiple sclerosis"],"prefix":"10.1136","volume":"87","author":[{"given":"L","family":"Zhovtis Ryerson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T C","family":"Frohman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Kister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Weinstock-Guttman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Tornatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Pawate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Bomprezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Kalina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z","family":"Rimler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Monson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Hoyt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Bradshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Fallon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Chamot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Bucello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Beh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Cutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Major","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Herbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E M","family":"Frohman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,2,25]]},"reference":[{"key":"key-10.1136\/jnnp-2015-312940-1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1527-3458.2007.00003.x","article-title":"Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases","volume":"13","author":"St\u00fcve","year":"2007","journal-title":"CNS Drug Rev"},{"key":"key-10.1136\/jnnp-2015-312940-2","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo- controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"key-10.1136\/jnnp-2015-312940-3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJMoa020696","article-title":"A controlled trial of natalizumab for relapsing multiple sclerosis","volume":"348","author":"Miller","year":"2003","journal-title":"N Engl J Med"},{"key":"key-10.1136\/jnnp-2015-312940-4","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta\u20141a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N Engl J Med"},{"key":"key-10.1136\/jnnp-2015-312940-5","unstructured":"Biogen Idec. http:\/\/www.tysabrihcp.com\/anti-jcv-antibody-test-hcp.xml (access 29 Sep 2015)."},{"key":"key-10.1136\/jnnp-2015-312940-6","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2015-312940-7","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1212\/WNL.52.5.1072","article-title":"A safety and pharmacokinetic study of intravenous natalizumab in patients with MS","volume":"52","author":"Sheremata","year":"1999","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2015-312940-8","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1586\/14737175.4.4.571","article-title":"Natalizumab: \u03b14\u2014integrin antagonist selective adhesion molecule inhibitors for MS","volume":"4","author":"Rudick","year":"2004","journal-title":"Expert Rev Neurother"},{"key":"key-10.1136\/jnnp-2015-312940-9","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1191\/1352458504ms1084oa","article-title":"An open label safety and drug interaction study of natalizumab in combination with interferon beta in patients with multiple sclerosis","volume":"10","author":"Vollmer","year":"2004","journal-title":"Mult Scler"},{"key":"key-10.1136\/jnnp-2015-312940-10","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/01.wnl.0000341766.59028.9d","article-title":"Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function","volume":"72","author":"Khatri","year":"2009","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2015-312940-11","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1212\/WNL.0000000000000355","article-title":"MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study","volume":"82","author":"Fox","year":"2014","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2015-312940-12","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/1352458511431073","article-title":"Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped","volume":"18","author":"Rispens","year":"2012","journal-title":"Mult Scler"},{"key":"key-10.1136\/jnnp-2015-312940-13","doi-asserted-by":"crossref","first-page":"e31784","DOI":"10.1371\/journal.pone.0031784","article-title":"Lymphocyte subsets show different response patterns to in vivo bound natalizumab\u2014a flow cytometric study on patients with multiple sclerosis","volume":"7","author":"Harrer","year":"2012","journal-title":"PLoS ONE"},{"key":"key-10.1136\/jnnp-2015-312940-14","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1111\/ane.12182","article-title":"Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?","volume":"129","author":"Wipfler","year":"2014","journal-title":"Acta Neurol Scand"},{"key":"key-10.1136\/jnnp-2015-312940-15","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/ana.20859","article-title":"Natalizumab effects on immune cell responses in multiple sclerosis","volume":"59","author":"Niino","year":"2006","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2015-312940-16","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00415-015-7655-1","article-title":"Body weight-based natalizumab treatment in adult patients with multiple sclerosis","volume":"262","author":"Tanaka","year":"2015","journal-title":"J Neurol"},{"key":"key-10.1136\/jnnp-2015-312940-17","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/ana.22074","article-title":"Natalizumab drug holiday in multiple sclerosis: poorly tolerated","volume":"68","author":"Killestein","year":"2010","journal-title":"Ann Neurol"},{"issue":"2","key":"key-10.1136\/jnnp-2015-312940-18","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1212\/01.wnl.0000265393.03231.e5","article-title":"Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients","volume":"70","author":"Vellinga","year":"2008","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2015-312940-19","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1001\/archneurol.2010.257","article-title":"Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy","volume":"68","author":"Miravalle","year":"2011","journal-title":"Arch Neurol"},{"key":"key-10.1136\/jnnp-2015-312940-20","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1212\/WNL.0b013e3181f07362","article-title":"Immune reconstitution inflammatory syndrome after withdrawal of natalizumab?","volume":"75","author":"Lenhard","year":"2010","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2015-312940-21","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1212\/WNL.0b013e31821e7c8a","article-title":"Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis","volume":"76","author":"O'Connor","year":"2011","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2015-312940-22","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1468-1331.2012.03794.x","article-title":"Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab","volume":"20","author":"Rossi","year":"2013","journal-title":"Eur J Neurol"},{"key":"key-10.1136\/jnnp-2015-312940-23","first-page":"367","article-title":"Natalizumab and PML [comment]","volume":"65","author":"Ranhosoff","year":"2009","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2015-312940-24","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jamaneurol.2014.63","article-title":"JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab","volume":"71","author":"Frohman","year":"2014","journal-title":"JAMA Neurol"},{"key":"key-10.1136\/jnnp-2015-312940-25","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMc1214233","article-title":"JC viremia in natalizumab treated patients with multiple sclerosis","volume":"368","author":"Major","year":"2013","journal-title":"N Engl J Med"},{"key":"key-10.1136\/jnnp-2015-312940-26","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/acn3.190","article-title":"CD4 cell response to interval therapy with natalizumab","volume":"2","author":"Berkovich","year":"2015","journal-title":"Ann Clin Transl Neurol"},{"key":"key-10.1136\/jnnp-2015-312940-27","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ana.20858","article-title":"Immune surveillance in multiple sclerosis patients treated with natalizumab","volume":"59","author":"St\u00fcve","year":"2006","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2015-312940-28","article-title":"Characterizing the natalizumab \u201cwearing off\u201d effect: Tysabri WOEs","author":"Katz","year":"2014"},{"key":"key-10.1136\/jnnp-2015-312940-29","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/1756285614540224","article-title":"Extended interval dosing of natalizumab: a two-center, 7-year experience","volume":"7","author":"Bomprezzi","year":"2014","journal-title":"Ther Adv Neurol Disord"}],"container-title":["Journal of Neurology, Neurosurgery & Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2015-312940","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T14:03:19Z","timestamp":1601042599000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2015-312940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,25]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2016,7,14]]},"published-print":{"date-parts":[[2016,8]]}},"alternative-id":["10.1136\/jnnp-2015-312940"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2015-312940","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,25]]}}}